IMV Inc IMVIF

Merck buys VelosBio

[Breakthorough1]

https://www.businesswire.com/news/home/20201105005543/en/Merck-to-Acquire-VelosBio Their results in lymphoma: "Objective tumor responses were not seen in patients with other tumor types but were observed in 7/15 (47%) of patients with MCL (4 partial; 3 complete) and in 4/5 (80%) of patients with DLBCL (2 partial; 2 complete). From start of therapy, 6/7 patients with responding MCL have responses ongoing at 35, 38, 45, 47, 50, and 58 wk and 2/4 patients with responding DLBCL have responses ongoing at 23 and 47 wk of followup." https://ash.confex.com/ash/2020/webprogram/Paper136373.html